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Introduction
The antipsychotic drug risperidone, 3-[2-[4-(6-fluoro-1,2-
benzisoxazol-3-yl)-1-piperidinyl]ethyl]-6,7,8,9-tetrahydro-2-methyl-
4H-pyrido[1,2-a] pyrimidin-4-one (Risp), belongs to the chemical 
class of benzisoxazoles and is one of the most widely used drugs in the 
treatment of autism spectrum disorders (ASD) [1,2]. ASD, which occur 
in 1 out of 150 individuals [1], include different neurodevelopment 
disorders that manifest mainly in the earlier years of life [3], 
affecting language, communication and reciprocal social interaction 
development [4]. Risp has low solubility in aqueous medium and, when 
orally administered, exhibits low bioavailability due to extensive first-
pass metabolism and high protein binding (>90%) [5]. Moreover, non-
targeted delivery usually results in numerous side effects. Since Risp 
target organ is the brain, it is necessary not only to develop a strategy 
to improve drug bioavailability, by avoiding first-pass metabolism, but 
also to achieve desired drug concentration at the site of action, thus 
reducing undesirable side effects [2]. 
In the last years, strategies with chemical therapies, particularly 
the design of nano-structured drug carrier systems [6], have been 
proposed to overcome these issues regarding ASD treatment. However, 
these kinds of carriers (plain, ultradeformable, stealth, pH-sensitive 
liposomes, immunoliposomes, nanoparticles and dendrimers) must 
be carefully designed and/or chosen because their pharmacokinetics, 
biodistribution, and tissue selectivity will exclusively depend on the 
nanocarrier’s structure [2,7-9]. In the last years, PAMAM dendrimers 
have been found to be useful to improve the solubility of low aqueous 
soluble drugs [10,11], so our previous work aimed to enhance Risp 
solubility, by means of PAMAM dendrimers [12]. 
In the present study, we studied the biodistribution and 
pharmacokinetics of the free Risp and DG4.5-Risp complexes given 
orally to healthy BALB/C mice. Behavioral studies were performed in 
healthy mice and toxicity studies in the zebrafish animal model. These 
studies were conducted to evaluate the potency of treatment with 
DG4.5-Risp complexes compared to the free Risp and the possible 
reduction of side effects seen in the traditional treatment.
Material and Methods
Preparation of DG4.5-Risp Complexes
Complexes were prepared as described before in Prieto et al. [12].
Animals
Biodistribution and pharmacokinetics 
Biodistribution and pharmacokinetics of Risp, were carried out 
by administering free Risp or DG4.5-Risp using BALB/C (25 g - 30 g) 
of the National University of Quilmes (Buenos Aires, Argentina).The 
animals were kept at 24 ± 1°C and 60-70% humidity, with light-dark 
cycles of 12 h, in stainless steel boxes. The animals were given tap water 
to drink and food ad libitum.
Behavioral test 
Mice: Male and female 8-15-week-old BALB/C mice were used 
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for behavioral tests. Animals of the same treatment, sex and age were 
housed in stainless steel cages, in a room under controlled temperature 
(24 ± 3°C), relative humidity (60-70%) and a 12 h light/dark cycle. Food 
and water were available ad libitum. All efforts were made to minimize 
the number of animals and their suffering. Both acute and chronic 
treatment experiments were conducted on the same animals. 
Zebrafish: A breeding stock of heterogeneous wild type zebrafish 
was purchased from a local pet shop and inbred in our facility, as 
described previously Kimmel et al. [13]. Sexually mature females and 
males (8-12 months old) were kept at a ratio of 3:1 in a glass aquarium 
filled with filtered tap water at 26 ± 1°C under 14 hour day/night light 
regime (lights ON = Zeitgeber Time zero (ZT0)). Fishes were fed with 
dry flakes (TetraMin PRO®) twice per day and with nauplia larvae of 
Artemia once a day ad libitum. For embryo production, four females 
and two males were crossed the night before the spawning day in traps 
made of plastic mesh, to prevent the eggs from cannibalism. Green algae 
and glass marbles were also added as spawning substrate. Collected 
eggs were maintained in a petri dish with E3 saline embryo medium 
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2, and 0.33 mM Mg2SO4) 
at 28.5°C, and examined for fertilization under a Nikkon TN-PSE80 
stereomicroscope. Non-fertilized eggs were discarded.
Biodistribution and Pharmacokinetics 
Treatment: The treatment was achieved by keeping the animals 
deprived of water 10 h before each test and using a gastric tube designed 
ad hoc by the working group. The maximum volume of treatment was 
50 µl. The maximum dose administered was 100 µg Risp, either in the 
free form or as complexes. The dose was selected as the recommended 
dosage for human treatment, being of 1.5 mg of drug per kilogram 
weight/individual (for individuals weighing less than 20 kg). We also 
considered the method detection limit and recovery percentage of the 
purification method.
Pharmacokinetics: Pharmacokinetic parameters of free Risp or 
complexes were obtained after oral treatment of a single dose of i) free 
Risp ii) DG4.5-Risp and iii) PBS as control. Group of animals (n=6) 
were used for each of the following times: 2, 5, 15, 30, 60 and 90 min. 
After 60 or 90 min, the animals were anesthetized and then sacrificed 
by cervical dislocation.
At predetermined times post-treatment, the animals were 
anesthetized and blood samples were withdrawn from the retro-orbital 
sinus with heparinized capillaries. Then, the plasma was separated 
from the red cells by centrifugation for 10 min, at 6000×g and stored 
at -20°C for subsequent extraction and Risp quantitation by High-
performance liquid chromatography (HPLC) [14,15]. Data obtained 
were corrected taking into account the recovery factor from previous 
extractions. Animals were anesthetized by inhalation with isoflurane 
prior to sample collection and sacrifice. Pharmacokinetic curves of Risp 
concentration (mg / ml) in plasma versus time allowed obtaining the 
following parameters: AUC, Cmax and tmax; using GraphPad Prism 
5.0 software and Microsoft Office Excel 2007.
Biodistribution: After 60 min or 90 min, the animals were 
anesthetized and sacrificed by cervical dislocation, their liver, brain and 
spleen extracted and then each organ washed with saline and weighed. 
Finally, they were stored at -20°C for subsequent extractions and Risp 
quantitation by HPLC. Data obtained were corrected taking into 
account the recovery factor from previous extractions.
Behavioral Test in Mice 
Treatment: Drugs were administered orally, once a day in the 
mornings, 60 min before the tests, for eight consecutive days. The net 
dose of Risp administered (either as free Risp or DG4.5-Risp) was of 
1 µg of Risp per gram of animal weight, in a concentration of 1 µg of 
Risp/µl in PBS buffer. Dose selection is based on the daily treatment in 
humans. Free DG4.5 mass administered corresponds with the DG4.5 
mass administered in the DG4.5-Risp complex in a volume of 1 µl in 
PBS per g of animal weight. Controls were given PBS in a dose of 1 µl of 
PBS per g of animal weight. 
Behavioral tests: All tests were performed between 10:00 and 12:00 
h in a silent room in controlled conditions of light and temperature (24 
± 3ºC). All animals were transported to the room 1 hour prior to the 
tests. Handling was minimal during the tests. Seven male and seven 
female mice were used for Risp, DG4.5-Risp and control treatments, 
whereas two males and two females were used for the treatment with 
DG4.5. Two series of tests were performed: acute, on day 1 of treatment 
and chronic, on day 8 of treatment. All animals were housed in groups 
of three or four animals of the same sex, age and treatment. Two days 
prior to the tests, for both the acute and chronic tests, animals were 
housed in solitary confinement to increase sociability and interaction. 
After the tests, animals were housed in community.
The tests were performed 60 min after treatment, consecutively, 
from the least to the most stressing test. Each test lasted 5 min. After 
the end of one test, the animal was immediately placed on the next test. 
This consecutive arrangement allowed an efficient performance and 
a minimum decrease in plasma drug levels [16,17]. Tests performed 
in the acute phase were the following: open field, performed first to 
increase exploration; elevated cross maze, as a measurement of anxiety; 
locomotion activity in the cage; sociability and social novelty; nest 
building, performed in the same cage that housed the animal in solitary 
confinement prior to the tests. The results of these tests were evaluated 
24 h later. The arrangement of the chronic tests was the following: 
Open field, elevated cross maze, elevated cross maze closed arm return, 
locomotion activity in cage and sociability and social novelty. 
The following tests were recorded in video for further analysis, and 
to avoid interference by the observers: Elevated cross maze, locomotion 
in cage and sociability and social novelty. All implementations used 
were placed in the same position and orientation. After every test, all 
surfaces in contact with animals were cleaned with alcohol and left to 
fully dry.
Tests: Open field: Locomotion and exploration were measured 
using a 64 x 57 cm wide cage with 5×5 cm grid drawn on the floor. 
The animal was placed in the center of the cage and allowed to explore 
the arena. The number of quadrants the animal entered in 5 min was 
recorded. General exploratory activity was evaluated according to 
previous descriptions [18,19].
Elevated cross maze: This assay is well characterized to measure 
anxiety-related behaviors in mice [19]. The elevated cross maze has four 
arms (two open and two enclosed, 50×10 cm long each) arranged in a 
cross. The maze is elevated 1 m from the ground. The animal is placed 
in the middle of the maze facing an open arm. Activity was recorded for 
5 min, and time spent in each arm, as well as entries and explorations 
into arms were analyzed. An entry into an arm is defined when the four 
pawns are in the arm, an exploration is defined when the animal sniffs 
or places two pawns in the center of the maze.
Elevated cross maze closed arm return: This assay was performed 
only in chronic tests. After the elevated cross maze test, the animal was 
lifted and placed on the end of an open arm. Time was calculated until 
the animal entered a closed arm, with a maximum waiting time of 5 min. 
Citation: Prieto MJ, del Rio Zabala NE, Marotta CH, Bichara D, Simonetta S, et al. (2013) G4.5 Pamam Dendrimer-Risperidone: Biodistribution and 
Behavioral Changes in In Vivo Model. J Nanomedine Biotherapeutic Discov 4: 121. doi:10.4172/2155-983X.1000121
Page 3 of 11
Volume 4 • Issue 1 • 1000121J Nanomedine Biotherapeutic DiscovISSN: 2155-983X JNBD an open access journal 
Locomotor activity in cage: Locomotor activity was evaluated in a 
familiar environment. The animal was placed in the cage that housed it 
for 2 days. The test was recorded for further analysis of total locomotion 
distance using ImageJ software. The cage size, distance and relative 
position of the camera were for the same in all tests. Measurements are 
relative to the control.
Sociability and social novelty: This assay was used to monitor 
social and territorial behaviors. After the locomotor test, an unfamiliar 
animal of the same sex and age, the intruder, was inserted in the cage. 
The animals used as intruders were housed with animals of the same 
sex and age and used exclusively for this test.
The interaction was recorded in video. The number of sniffing, 
crawling over, following, approaching and distancing, dominant 
hierarchies, aggressive behaviors and attacks were evaluated. Fighting 
is more common in male than in female mice. If the attacks were too 
violent, animals were separated.
To evaluate dominant hierarchy, a scoring system of 1 to 10 divided 
into four groups was formulated. Groups from 1 to 3 presented only 
following and sniffing. Groups from 4 to 6 presented not only following 
and sniffing but also crawled over the intruder. Groups from 6 to 8 
presented all the above together with bites and attacks. Groups 9 and 10 
presented the highest levels of violent attacks and fighting.
Nest building: As a measure of social activity, we evaluated nest 
building. Male and female mice build nests using various types of 
materials [20]. Nests are scored for their height, number of entrances, 
shape, quality, manipulation of materials and localization in the cage. A 
well-built nest has the shape of a cocoon with walls that house a cave 
with one or more entrances [21]. Low material handling reflects a low 
elaborated nest. After completion of the acute tests, 3 g of commercial 
cotton was introduced in the cage that housed the animal in solitary 
confinement, 24 h later, and the building quality analyzed. The animal 
was then returned to the community cage.
Behavioral test in zebra fish-toxicity 
Automated measurement of larval activity events: The system 
is based on an infrared microbeam arrangement that detects light 
refraction through the zebrafish body, essentially as described 
elsewhere [22,23]. Animals were placed in 96 well microplates and 
subjected to illumination with two infrared microbeams per well (100 
µm wide and of 880 nm wavelength each). A transient fluctuation 
in the signal is generated when larvae move across the light beam 
and received by a phototransistor array. Light signals output were 
digitalized by a multichannel ADC system (WMicrotracker, Designplus 
SRL, Argentina) at a sample rate of 10 samples/sec and 10 bit resolution. 
Data were acquired with an IBM-PC connected via RS232 protocol 
and processed by software programmed in MS-Visual Basic. Signal 
activity events (defined as the times that larvae cross through infrared 
microbeams) were calculated in real time by detecting small fluctuations 
in the signal received. Variations greater than 3% in the signal received 
(empirically determined threshold) were considered as activity events. 
Swimming activity was calculated summing up the number of activity 
events for 15 minutes. Data are reported as the averaged activity event 
recorded for each microbeam pair ± SEM.
Treatment: For the treatment, 48-hpf non-hatched zebrafish 
embryos were placed in each well of a 96-well plate containing E3 
medium and incubated for additional 48 h at 28ºC. At 4 dpf, the 
medium was replaced by 250 µl of solutions of the different compounds 
or E3 (control). For each assay, 12 technical replicates were used for 
each dilution. Activity events were recorded for 15 min, three times 
at 4, 5, 6 and 7 dpf after the addition of the compound tested, at room 
temperature [22]. 
Ethics Statement: All animal procedures were performed in strict 
accordance with National Institutes of Health rules for animal care and 
maintenance. The study protocols were approved by the Universidad 
Nacional de Quilmes Institutional Animal Care Committee.
Statistical analysis
Data are presented as mean ± standard deviation and analyzed 
by one-way analysis of variance (ANOVA) and Tukey's Multiple 
Comparison Test using GraphPad Prism v. 5. Only values with P<0.05 
were accepted as significant.
Results and Discussion 
Pharmacokinetics 
Risp concentration in plasma after oral treatment of DG4.5-Risp 
complexes was significantly lower (P <0.05) than that found after oral 
treatment of the free Risp (Figure 1). The maximum concentration of 
Risp in circulation was observed 15 min post- treatment for both the 
free Risp and the DG4.5-Risp complexes. Regarding this parameter, the 
Cmax of the DG4.5-Risp complexes decreased 4.5 times compared to 
the Cmax of free Risp. In addition, the AUC0-90 of the DG4.5-Risp 
complexes was almost 5 times lower than the AUC0-90 of the free Risp, 
although the drug dosage administered was the same (Table 1).
Biodistribution 
Although the amount of drug reaching each organ studied was 
higher for animals administered DG4.5-Risp after 60 min, this difference 
was not significant (P>0.05). However, when the biodistribution of the 
drug concentration was analyzed in the brain at 90 min post- treatment, 
the difference observed was quantitatively significant (P <0.05) (Figure 
2). 
The high density of surface groups (one amine-group/nm2 for DG4 
and 1.6 carboxylic-groups/nm2 for DG4.5) combined with a small size 
(4.5 to 5.0 nm in diameter for DG4-spheres and DG4.5-ellipsoids) gives 
these dendrimers a large area/volume ratio. This renders dendrimers 
with an unusual ability to establish surface interactions with cell 
Figure 1: Pharmacokinetics of risperidone in plasma. Blood Concentration of 
Risperidone versus time (n=6).
Cmáx (μg/ml) tmáx (min) AUC0-90 (μg/ml/min)
DG4.5-Risp 3.42 ± 0.78 15 80,28
Risp 7.97 ± 1.72 15 395,90
Table 1: Pharmacokinetic parameters after Risp oral treatment in the free form and 
as the DG4.5-Risp complexes (n=6).
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membranes [24,25]. Besides interacting with membrane lipids [26], the 
dendrimers possess the ability to modify protein conformation [27]. On 
the other hand, complexation of Risp with dendrimers could modify 
their internal volume and hence their size together with the density of 
surface groups, and it is known that such surface modification changes 
the interaction between DG4.5 and cells [28,29].
Based on the above conclusions, the pharmacokinetics and 
biodistribution of the free and complexed Risp were studied in healthy 
mice, seeking to modify the parameters obtained with the free Risp.
DG4.5-Risp complexes were not orally administered to prove 
increase absorption of Risp, since it is known that this process is fast 
and highly efficient (70-90% of the drug initially administered) [30]. 
However, an increased plasma level makes the drug more susceptible of 
being metabolized, generating widespread distribution and decreasing 
its arrival at the target organ, and hence causing severe side effects. 
For this reason, we investigated whether Risp, once complexed to 
DG4.5, could be absorbed by the gastrointestinal tract, and thus 
show a modified biodistribution and pharmacokinetic profile and if 
these differential parameters ideally meet the desirable levels for the 
treatment of non-toxic side effects.
After oral treatment, DG4.5-Risp levels were significantly lower in 
blood than those of free Risp, when the same dose was administered. 
This trend was observed for all the pharmacokinetic profiles studied. 
Furthermore, after 90 min post- treatment, the animals administered 
with free Risp still exhibited a high level of circulating Risp. This trend 
was not observed in animals administered DG4.5-Risp and in fact, even 
after 30 min, these animals showed very low levels of circulating Risp. 
These are relevant observations because, after coming into circulation, 
Risp highly binds to plasma proteins and metabolizes with widespread 
distribution into places where no therapeutic activity is needed.
Continuing with the analysis of the data and results obtained for the 
pharmacokinetic profile of the drug, it is necessary to consider several 
factors. First, the complexation of Risp to DG4.5 might have decreased 
the absorption of the drug. This could be explained by the observed 
decrease in the circulating Risp concentration, which is also in good 
agreement with the results obtained by Wiwattanapatapee et al. [31]. 
More so, flow cytometry and confocal microscopy have shown that 
DG4.5 cannot be retained by the mucin of the mucosa, because of the 
anionic macromolecules present in the gut [7,8].
There are few reports concerning the ability of dendrimers to cross 
the gastrointestinal membrane. Wiwattanapatapee et al. [31] investigated 
the transport of cationic and anionic dendrimers in the intestine 
of adult rats, by in vitro assays. Their results suggest that transport 
through the gut membrane is dependent on electrostatic interactions, 
and it is influenced by size. They also found that the absorption of the 
dendrimers of intermediate generations is considerably higher than 
that of small ones and that dendrimers of smaller generation were 
transported through third-phase endocytosis. 
In contrast, both anionic and cationic dendrimers of generations in 
between were found to be absorbed by adsorptive endocytosis, either 
specific or nonspecific. Florence et al. [32] studied the absorption of 
dendrimers after oral treatment and found that 6 hours post-treatment, 
the amount of dendrimers accumulated in the stomach, small intestine 
and large intestine as a whole was 20% of the initial dose. This author 
also observed that the incorporation of dendrimers in the small intestine 
took place preferably through Peyer's patches, while enterocytes played 
the most important role in the embodiment in the large intestine. 
The incorporation of a hydrophobic drug could modify not only the 
spherical shape of DG4.5 but also its surface groups and/or the charged 
groups exposed. Thus, the intestinal absorption of the drug would 
depend on the physicochemical characteristics of the new complex 
molecule formed. Concerning the biodistribution at 60 min after oral 
treatment of the complexes, the amount of drug in the organs analyzed 
remained almost unchanged compared with the same dose of free Risp. 
However, the most remarkable result in terms of the biodistribution 
studies observed in animals administered with the complexes was a 
significant increase in the drug concentration reaching the brain (white 
body) 90 minutes post-treatment.
Considering that the chromatographic method can only quantify 
the unmetabolized drug, the results suggest an increased arrival of 
dendrimers at the target organ, where DG4.5 act as "protector" of Risp, 
decreasing its metabolization and consequently the production of 
9-OH-Risp. It has been reported that for the treatment with Risp, the 
drug is metabolized to 9-OH-Risp as a consequence of hydroxylation 
of the drug by cytochromes CYP2D6 and CYP3A mainly in the liver. 
This is the most important metabolic pathway and the levels of the Risp 
dose administered consumed are up to 31% [33]. Although 9-OH-
Risp has pharmacological activity, it binds strongly to plasma proteins, 
decreasing the bioavailability of pharmacologically active components 
and generating a generalized distribution responsible for many of the 
side effects of the regular treatment. The main previous results include 
Figure 2: Risperidone drug biodistribution in organs. Risp concentration found for different organs studied after 60 and 90 min (n=6).
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weight gain and hyperprolactinemia [34,35]. Therefore, the proposed 
alternative of using dendrimers as drug delivery systems to provide 
protection from enzymatic metabolism is mainly to reduce the side 
effects of the treatment.
Regarding the dendrimers protective action contributing to the 
transported molecule, we have previously found that the formulation [8] 
SDZ-DG4 and SDZ-DG4.5 complexes achieved a reduced metabolism 
of SDZ by enzymes such as NAT and CYP2C8/9. From this point of 
view, it would be possible to minimize the generation of toxic hydroxyl 
products, hence the damage caused by acetylation and hydroxylation, 
and alterations in enzyme phenotypes that contribute to toxicity if the 
drug is incorporated into the vehicle. 
We were able to modify both the biodistribution and 
pharmacokinetic parameters of Risp incorporated in anionic DG4.5 
transporter. Given these results, the differential profiles observed would 
establish the basis for an efficient nanosized drug carrier system. This 
nano-system could improve Risp arrival at its target organ and the 
protection given by the dendrimers will represent a decrease in the 
adverse effects of the treatment.
Behavioral
Behavioral studies in mice
i. Studies of the Behavior of Mice in their Home-Cage and 
of their Health in General: The behavior of mice under different 
treatments was evaluated in their home-cage. As a measurement of 
activity in the home-cage related to social behavior, we evaluated nest 
building by adding cotton in each cage. After 24 h of added material, 
all mice showed clear evidence of nest building. No physical differences 
were observed in the fur, general health status and piloerection of 
moustaches when comparing the results of the different treatments. All 
animals reacted to external stimuli and had normal visual reflection, 
and no tardive dyskinesia was observed. The results of free dendrimers 
tests are not shown because they were identical to those administered 
with PBS.
ii. Outfield: The exploratory locomotion shown by the animals 
administered PBS was much higher than that for both treatments with 
Risp (p<0.05). A decrease in the exploratory locomotion was observed 
in females treated with the complexes, both in the acute and chronic 
treatments, with respect to the free Risp. This was not the case for males 
treated with the complexes, which presented the same exploratory 
activity as those treated with the free drug (Figures 3 and 4).
iii. Elevated Cross Maze: Anxiety was evaluated based on the 
location of the animal in the maze. A greater amount of time in the 
open arm is taken as low anxiety, whereas an animal that spends most 
of the time in the closed arm reflects higher levels of anxiety. This was 
used to describe the animal as anxious or not anxious. Although the 
degree of anxiety in mice of both treatments was significantly lower 
than that of controls, no significant differences were observed between 
those treated with the free drug and those treated with the complex 
Figure 3: Outfield. Behavioral Studies in Mice with acute and chronic administration. Number of quadrants traversed in the outfield by female mice (n=7). * p<0.05, ** 
p<0.01. 
Figure 4: Outfield. Behavioral Studies in Mice with acute and chronic administration. Number of quadrants traversed in the outfield by male mice (n=7). * p<0.05, ** 
p<0.01.
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(Table 2). 
iv. Inspections: Regarding inspections in the maze, females under 
the acute treatment showed 60% of inspections, against 0% observed 
in mice treated with Risp and DG4.5-Risp. Regarding females under 
the chronic treatment, 71% of the control group, 43% of mice treated 
with Risp and 57% of mice treated with DG4.5-Risp showed inspection 
behavior. These results show a greater tendency of inspection in the 
animals chronically treated with the DG4.5-Risp complex (Table 3). 
Regarding male control animals under the acute treatment, 51% 
showed inspection behavior compared to 14% of those treated with 
Risp or DG4.5-Risp. In those under the chronic treatment, the number 
of inspections performed by control animals was of 100%, and 28% and 
14% of the male animals treated with Risp and DG4.5-Risp complexes 
showed inspection behavior, in contrast to that observed in females 
(Table 3).
Comparing genders, we observed that in the acute treatments with 
Risp and DG4.5-Risp males performed significantly more inspections 
than females, whereas in the chronic treatments, control males showed 
significantly more inspections than females, while for Risp and 
DG4.5-Risp treatments, males showed a smaller fraction of performed 
inspections than females.
v. Entries: Females of both treatments did not enter the center 
of the maze or in the open arm area (results not shown). In the acute 
test, control males did not enter the center of the maze (results not 
shown). In the case of chronic tests, although no significant differences 
were found, controls showed a greater number of entries than those 
administered with Risp. Again, animals administered DG4.5-Risp 
performed no entries.
vi. Return to the undercover arm: This test, which was performed 
only under chronic treatment, showed no significant differences in 
females between animals administered Risp or DG4.5-Risp, although 
the difference of both with the control group was significant. In the case 
of males, results were similar (results not shown).
vii. Locomotion: Locomotion was measured as a parameter related 
to distances using the Image J. program. For all groups, differences 
between controls and animals administered with Risp or DG4.5-Risp 
were significant, whereas differences between treatments with Risp 
were not significant (Figures 5 and 6).
viii. Sociability and Social Novelty
A. Approach: It is more common to see a greater number of 
approaches in males than in females, due to their higher territorial 
activities. In both groups of animals, there was an increase in the 
% of animals showed anxiety
Males Female
Control Risp DG4.5-Risp Control Risp DG4.5-Risp
Acute 86 28 28 60 28 14
Chronic 100 43 43 100 71 86
Table 2: Percentage of male and female animals referred to all that experimented 
anxiety in the elevated cross maze. Animals that remained permanently in a closed 
area were considered anxious (n=7).
% animals showed inspection behavior
Males Female
Control Risp DG4.5-Risp Control Risp DG4.5-Risp
Acute 51 14 14 60 0 0
Chronic 100 28 14 71 43 57
Table 3: Percentage of females and males that performed inspections in the 
elevated cross maze (n=7).
Figure 5: Locomotion. Behavioral Studies in Mice with acute and chronic administration. Relative locomotion for female mice in both the acute and chronic treatments 
(n=7). * p<0.05, ** p<0.01, ***p<0.001.
Figure 6: Locomotion. Behavioral Studies in Mice with acute and chronic administration. Relative locomotion for female mice in both the acute and chronic treatments 
(n=7). * p<0.05, ** p<0.01, ***p<0.001. 
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approaches of chronic versus acute group, due to habituation of 
animals to handling and acute treatment tests. Statistical studies 
showed that, for all groups, the differences between the two 
treatments and controls are significant. For the group of females with 
chronic treatment approaches the percentage for DG4.5-Risp groups 
is significantly less than for the free Risp. In the case of males in 
the two trial groups, both treatments with antipsychotic showed no 
differences (Figures 7 and 8).
B. Sniff: The controls of all groups significant differences compared 
with administered with Risp or DG4.5-Risp treatments. For acute 
treatments, females showed no significant differences in the number of 
sniffs between the two treatments. Animals administered Risp-DG4.5 
showed a tendency to have fewer sniffs. Males showed no significant 
differences in acute treatments but there was a trend indicating less 
sniffing when administered the complex than when administered the 
free drug. For tests with chronic treatment, males and females observed 
significant lower number of sniffing for the group administered with 
the complex. The DG4.5-administered groups showed lower number 
of sniffs than those administered Risp, showing greater potency with 
chronic treatments (Figures 9 and 10).
C. Fights: Female groups showed no fights. Males in acute 
treatments showed that 42% of control animals clashed against 14% of 
animals administered Risp. None of the animals administered DG4.5-
Risp clashed. In chronic treatments, clashes percentage of the control 
groups was higher, but animals treated with DG4.5-Risp or Risp had no 
confrontations (data not shown). 
D. Dominance: All groups showed significant differences between 
those treated with Risp or DG4.5-Risp and control groups, except 
females treated with Risp as compared with control under the acute 
treatment. Males under the acute treatment showed significant 
differences between Risp and DG4.5-Risp complexes. For chronic 
cases, no difference was observed between treatments. Females showed 
significant differences between treatments for both Risp and DG4.5-
Risp (Figures 11 and 12).
Figure 7: Sociability and Social Novelty. Approach. Number of approaches performed by female groups (n=7).* p<0.05,** p<0.01, ***p<0.001.
Figure 8: Sociability and Social Novelty. Approach. Number of approaches performed by males groups (n=7).* p<0.05,** p<0.01, ***p<0.001.
Figure 9: Sociability and Social Novelty. Sniff. Number of sniffs of female mice with an intruder in sight (n=7).* p<0.05,** p<0.01, ***p<0.001.
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ix. Weights: Weights were monitored daily. After 8 days of 
treatments in males (Risp, DG4.5-Risp or PBS), no increases or 
decreases were observed in weight for both treatments versus control. 
However, females showed a strong increase in weight when treated with 
the free drug, indicating a highly significant difference from the control. 
This increase was not observed under the treatment with DG4.5-Risp 
(Figures 13 and 14).
x. Nest Building: The mice administered with PBS formed a nest 
with far more elaboration, more compact and with more entries than 
those given Risp or DG4.5-Risp. All mice treated with Risp or DG4.5-
Risp formed nests and showed no differences in the quality of their 
constructions. During the resting periods, all the mice preferred nesting.
Once Risp was complexed with DG4.5, the evaluation of its 
effectiveness in healthy mice of both sexes was necessary. It is known 
that oral absorption of Risp is fast and efficient (70 to 90%) [30], but the 
generation of a systemic distribution reduces the concentration of the 
drug in the target site and produces serious side effects.
The animals showed good health and normal behavior, so the 
consecutive evaluation method worked well in pursuing complete 
course of each trial. The handling of animals was minimal and the stress 
was minimized. The experimental conditions were maintained during 
all trials.
The previous behavioral studies in mice showed the results of 
complex DG4.5-Risp versus free Risp.These studies were designed in 
search for differences in efficacy and/or potency of the complexed drug 
versus the free drug. All tests showed that the potency of the DG4.5-
Risp was equal to or greater than that of the free Risp.
As for the weight gain, both groups of treated males showed no 
changes as compared to controls. However, females treated with Risp 
showed a strong and significant weight increase when compared to 
Figure 10: Sociability and Social Novelty. Sniff. Number of sniffs of male mice with an intruder in sight (n=7). * p<0.05, ** p<0.01, ***p<0.001.
Figure 11: Sociability and Social Novelty. Dominance. Level of dominance for female mice (n=7). * p<0.05, ** p<0.01, ***p<0.001.
Figure 12: Sociability and Social Novelty. Dominance. Level of dominance for male mice (n=7). * p<0.05, ** p<0.01, ***p<0.001.
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controls. This increase was not observed when treated with the DG4.5-
Risp complex. The weight increase in female mice was caused by the fact 
that Risp is related to increased levels of prolactin due to the blocking 
activity of the D2 receptors. This increase was not present when animals 
were given the complex.
In conclusion, we were able to modify the behavioral parameters of 
Risp by complexing it to DG4.5 dendrimer. The results evidenced that 
DG4.5-Risp complexes exert equal or greater potency than that of free 
Risp. On this basis, we designed an efficient drug transport by means 
of nanosystems. The DG4.5-Risp complex allows for non-systemic Risp 
distribution, higher concentration at the target site, Risp protection 
from enzymatic reactions, hence reducing the metabolite 9OH-RSP. 
The greatest achievement is that it allows lowering the doses of active 
Risp, hence lowering the amount of drug administered per patient with 
the same therapeutic effect and a marked reduction in side effects.
Zebrafish behavioral studies-toxicity
Figure 15 shows the spontaneous swimming activity of zebrafish 
treated with either free Risp or DG4.5-Risp. When zebrafish were treated 
with free Risp 25 μM, the swimming activity decrease significantly. 
However, this decrease was not observed when treated with the same 
concentration of the drug complexed with DG4.5 dendrimers. A 
decrease in spontaneous swimming is usually considered as a factor 
indicating fish toxicity [22,36,37]. Hence, the beneficial effect of 
dendrimers is to decrease Risp toxicity.
Conclusions
We first studied the biodistribution and pharmacokinetics of Risp 
and DG4.5-Risp given orally to healthy BALB/C mice. Risp plasma 
concentration at any time post-treatment was significantly lower 
in mice subjected to DG4.5-Risp than in mice administered the free 
Risp. The addition of the drug to the dendrimers allowed the drug to 
reach the brain 90 minutes after the treatment. The behavioral studies 
performed in mice indicated that the complex had a power equal to or 
greater than commercial Risp. Body weight did not increase in treated 
females. On the other hand, we used the zebrafish (Danio rerio) as a 
model to study toxicity and other related fields of biomedicine [13,38-
41]. When the drug was complexed to dendrimers, toxicity decreased. 
9OH-RSP has pharmacological activity and is responsible for many of the 
side effects of the drug, along with weight gain and hyperprolactinemia 
in females [34,35]. 
Figure 14: Weight increase for day 1 and day 8 of the treatment. The value 100 % represents the weight at beginning of the treatment (n=7). * p<0.05, ** p<0.01.
Figure 15: Zebrafish Behavioral Studies – Toxicity. Percentage of swimming activity vs control. The value 100 % corresponds to control (n=12). * p<0.05, ** p<0.01.
Figure 13: Weight comparison for males and females for day 1 and day 8 of the treatment (n=7).
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The addition of Risp to dendrimers to generate a complex DG4.5-
Risp protects the drug from enzymatic metabolism of 9OH-RSP. We 
have previously in Prieto et al. [8] reported the strategy followed to 
obtain complexes of SDZ-DG4 and SDZ-DG4.5 and found a reduced 
metabolism of SDZ by enzymes such as NAT and CYP2C8/9 [8]. 
This dendrimer protection may significantly reduce the generation of 
hydroxylated and/or acetylated enzymatic toxics, thereby decreasing 
the toxicity of the drug. Results demonstrate that the dendrimerization 
of the drug generates an efficient nanotransport system, less toxic than 
a greater amount of Risp reaching the target site of action and above 
all with a lower concentration of the drug in blood. This decrease in 
side effects and toxic metabolites increases the therapeutic action of the 
drug in the brain.
Acknowledgment
This research was supported by a grant from Universidad Nacional de Quilmes 
(Buenos Aires, Argentina). Silvia del Valle Alonso is a member of Consejo Nacional 
de Investigaciones Científicas y Técnicas (CONICET, Argentina) and IMBICE, 
CICPBA (Provincia de Buenos Aires, Argentina). M.J. Prieto acknowledges 
fellowships from CONICET, Argentina. We thank Angel Jones and Dr. Nora Vizioli 
of the Faculty of Pharmacy and Biochemistry, University of Buenos Aires. We would 
also like to thank Sebastian Graziati of Institute of Molecular and Cellular Biology 
of Rosario (IBR), Santa Fe, Argentina, PhD Santiago Plano of Chronobiology 
laboratory, UNQ and Ministerio Nacional de Ciencia, Tecnología e Innovación 
Productiva (MINCYT) grants.
References
1. Courchesne E, Pierce K, Schumann CM, Redcay E, Buckwalter JA, et al. 
(2007) Mapping early brain development in autism. Neuron 56: 399-413.
2. Kumar M, Misra A, Babbar AK, Mishra AK, Mishra P, et al. (2008) Intranasal 
nanoemulsion based brain targeting drug delivery system of risperidone. Int J 
Pharm 358: 285-291. 
3. Marshall CR, Noor A, Vincent JB, Lionel AC, Feuk L, et al. (2008) Structural 
variation of chromosomes in autism spectrum disorder. Am J Hum Genet 82: 
477-488. 
4. Malone RP, Waheed A (2009) The role of antipsychotics in the management 
of behavioural symptoms in children and adolescents with autism. Drugs 69: 
535-548.
5. Mannens G, Meuldermans W, Snoeck E, Heykants J (1994) Plasma protein 
binding of risperidone and its distribution in blood. Psychopharmacology (Berl) 
114: 566-572.
6. Svenson S (2009) Dendrimers as versatile platform in drug delivery applications. 
Eur J Pharm Biopharm 71: 445-462.
7. Prieto MJ, Bacigalupe D, Pardini O, Amalvy JI, Venturini C, et al. (2006) 
Nanomolar cationic dendrimeric sulfadiazine as potential antitoxoplasmic 
agent. Int J Pharm 326: 160-168.
8. Prieto MJ, Schilrreff P, Tesoriero MV, Morilla MJ, Romero EL (2008) Brain 
and muscle of Wistar rats are the main targets of intravenous dendrimeric 
sulfadiazine. Int J Pharm 360: 204-212.
9. Prieto MJ, Temprana CF, del Río Zabala NE, Marotta CH, Alonso Sdel V 
(2011) Optimization and in vitro toxicity evaluation of G4 PAMAM dendrimer-
risperidone complexes. Eur J Med Chem 46: 845-850.
10. Cheng Y, Li M, Xu T (2008) Potential of poly(amidoamine) dendrimers as drug 
carriers of camptothecin based on encapsulation studies. Eur J Med Chem 43: 
1791-1795.
11. Cheng Y, Qu H, Ma M, Xu Z, Xu P, et al. (2007) Polyamidoamine (PAMAM) 
dendrimers as biocompatible carriers of quinolone antimicrobials: an in vitro 
study. Eur J Med Chem 42: 1032-1038.
12. Prieto MJ, Del RZ, Marotta NE, Carreno Gutierrez CH, Arevalo Arevalo R, et al. 
(2013) Optimization and in vivo toxicity evaluation of G4.5 PAMAM Dendrimer-
Risperidone complexes. In review. 
13. Kimmel CB, Ballard WW, Kimmel SR, Ullmann B, Schilling TF (1995) Stages of 
embryonic development of the zebrafish. Dev Dyn 203: 253-310.
14. Shen YL, WU HL, Ko WK, Wu SM (2002) Simultaneous determination 
of clozapine, clozapine N-oxide, N-desmethylclozapine, risperidone, and 
9-hidroxyrisperidone in plasma by high performance liquid chromatography 
with ultraviolet detection. Analytica Chimica Acta 460: 201-208. 
15. Zhang G, Terry AV Jr, Bartlett MG (2007) Simultaneous determination of five 
antipsychotic drugs in rat plasma by high performance liquid chromatography 
with ultraviolet detection. J Chromatogr B Analyt Technol Biomed Life Sci 856: 
20-28.
16. Crawley JN (2007) Mouse behavioral assays relevant to the symptoms of 
autism. Brain Pathol 17: 448-459.
17. Crawley JN, Chen T, Puri A, Washburn R, Sullivan TL, et al. (2007) Social 
approach behaviors in oxytocin knockout mice: comparison of two independent 
lines tested in different laboratory environments. Neuropeptides 41: 145-163. 
18. Silverman JL, Tolu SS, Barkan CL, Crawley JN (2010) Repetitive self-grooming 
behavior in the BTBR mouse model of autism is blocked by the mGluR5 
antagonist MPEP. Neuropsychopharmacology 35: 976-989.
19. Silverman JL, Turner SM, Barkan CL, Tolu SS, Saxena R, et al. (2011) Sociability 
and motor functions in Shank1 mutant mice. Brain Res 1380: 120-137.
20. Bult A, Lynch CB (1997) Nesting and fitness: lifetime reproductive success in 
house mice bidirectionally selected for thermoregulatory nest-building behavior. 
Behav Genet 27: 231-240.
21. Moretti P, Bouwknecht JA, Teague R, Paylor R, Zoghbi HY (2005) Abnormalities 
of social interactions and home-cage behavior in a mouse model of Rett 
syndrome. Hum Mol Genet 14: 205-220.
22. Bichara D, Calcaterra NB, Arranz S, Armas P, Simonetta SH (2013) Set-up of 
an infrared fast behavioral assay using zebrafish (Danio rerio) larvae, and its 
application in compound biotoxicity screening. Journal of applied toxicology. 
23. Simonetta SH, Golombek DA (2007) An automated tracking system for 
Caenorhabditis elegans locomotor behavior and circadian studies application. 
J Neurosci Methods 161: 273-280.
24. Fischer D, Li Y, Ahlemeyer B, Krieglstein J, Kissel T (2003) In vitro cytotoxicity 
testing of polycations: influence of polymer structure on cell viability and 
hemolysis. Biomaterials 24: 1121-1131.
25. Mecke A, Uppuluri S, Sassanella TM, Lee DK, Ramamoorthy A, et al. (2004) 
Direct observation of lipid bilayer disruption by poly(amidoamine) dendrimers. 
Chem Phys Lipids 132: 3-14.
26. DomaÅ„ski DM, Klajnert B, Bryszewska M (2004) Influence of PAMAM 
dendrimers on human red blood cells. Bioelectrochemistry 63: 189-191.
27. Klajnert B, Bryszewska M (2002) Fluorescence studies on PAMAM dendrimers 
interactions with bovine serum albumin. Bioelectrochemistry 55: 33-35.
28. Han M, Chen P, Yang X (2005) Molecular dynamics simulation of PAMAM 
dendrimer in aqueous solution. Polymer 46: 3481-3488. 
29. Withers JR, Aston DE (2006) Nanomechanical measurements with AFM in the 
elastic limit. Adv Colloid Interface Sci 120: 57-67.
30. Ereshefsky L, Lacombe S (1993) Pharmacological profile of risperidone. Can J 
Psychiatry 38 Suppl 3: S80-88.
31. Wiwattanapatapee R, Carreño-Gómez B, Malik N, Duncan R (2000) Anionic 
PAMAM dendrimers rapidly cross adult rat intestine in vitro: a potential oral 
delivery system? Pharm Res 17: 991-998.
32. Florence AT, Sakthivel T, Toth I (2000) Oral uptake and translocation of a 
polylysine dendrimer with a lipid surface. J Control Release 65: 253-259.
33. Fang J, Bourin M, Baker GB (1999) Metabolism of risperidone to 
9-hydroxyrisperidone by human cytochromes P450 2D6 and 3A4. Naunyn 
Schmiedebergs Arch Pharmacol 359: 147-151.
34. Canitano R, Scandurra V (2011) Psychopharmacology in autism: an update. 
Prog Neuropsychopharmacol Biol Psychiatry 35: 18-28.
35. Melkersson KI (2006) Prolactin elevation of the antipsychotic risperidone is 
predominantly related to its 9-hydroxy metabolite. Hum Psychopharmacol 21: 
529-532.
36. Airhart MJ, Lee DH, Wilson TD, Miller BE, Miller MN, et al. (2007) Movement 
disorders and neurochemical changes in zebrafish larvae after bath exposure 
to fluoxetine (PROZAC). Neurotoxicol Teratol 29: 652-664.
37. Prieto MJ, Gutierrez HC, Arévalo AR, Chiaramoni NS, Alonso SDV (2012) 
Effect of Risperidone and Fluoxetine on the Movement and Neurochemical 
Changes of Zebrafish. Open Journal of Medicinal Chemistry 2: 129-138. 
Citation: Prieto MJ, del Rio Zabala NE, Marotta CH, Bichara D, Simonetta S, et al. (2013) G4.5 Pamam Dendrimer-Risperidone: Biodistribution and 
Behavioral Changes in In Vivo Model. J Nanomedine Biotherapeutic Discov 4: 121. doi:10.4172/2155-983X.1000121
Page 11 of 11
Volume 4 • Issue 1 • 1000121J Nanomedine Biotherapeutic DiscovISSN: 2155-983X JNBD an open access journal 
38. Chakraborty C, Hsu CH, Wen ZH, Lin CS, Agoramoorthy G (2009) Zebrafish: a 
complete animal model for in vivo drug discovery and development. Curr Drug 
Metab 10: 116-124.
39. Hu YL, Qi W, Han F, Shao JZ, Gao JQ (2011) Toxicity evaluation of 
biodegradable chitosan nanoparticles using a zebrafish embryo model. Int J 
Nanomedicine 6: 3351-3359.
40. McGrath P, Li CQ (2008) Zebrafish: a predictive model for assessing drug-
induced toxicity. Drug Discov Today 13: 394-401.
41. Peterson RT, Macrae CA (2012) Systematic approaches to toxicology in the 
zebrafish. Annu Rev Pharmacol Toxicol 52: 433-453.
Submit your next manuscript and get advantages of OMICS 
Group submissions
Unique features:
• User friendly/feasible website-translation of your paper to 50 world’s leading languages
• Audio Version of published paper
• Digital articles to share and explore
Special features:
• 300 Open Access Journals
• 25,000 editorial team
• 21 days rapid review process
• Quality and quick editorial, review and publication processing
• Indexing at PubMed (partial), Scopus, DOAJ, EBSCO, Index Copernicus and Google Scholar etc
• Sharing Option: Social Networking Enabled
• Authors, Reviewers and Editors rewarded with online Scientific Credits
• Better discount for your subsequent articles
Submit your manuscript at: www.editorialmanager.com/pharma
Citation: Prieto MJ, del Rio Zabala NE, Marotta CH, Bichara D, Simonetta S, 
et al. (2013) G4.5 Pamam Dendrimer-Risperidone: Biodistribution and Behav-
ioral Changes in In Vivo Model. J Nanomedine Biotherapeutic Discov 4: 121. 
doi:10.4172/2155-983X.1000121
